Pancreatic Cancer Research

ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergActive in the last 2 years

Helmut Oettle

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5077420997, A5109115262. Sources: OpenAlex.

Their work

Papers
38 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
85
Papers, trials and grants by year

2011: 4 papers · 2012: none · 2013: 3 papers · 2014: 5 papers · 2015: 4 papers · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 38

  1. Reply to: "Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology," "Key Methodological Considerations in the Interpretation of the CONKO-007 Trial,… Last author DOI 10.1200/jco-25-02926↗
  2. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Last author DOI 10.1200/jco-25-03004↗
  3. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Last author DOI 10.1200/jco-24-01502↗
  4. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping. Co-author DOI 10.1002/2056-4538.12377↗
  5. Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116… Last author DOI 10.1007/s00432-024-05827-x↗
  6. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
  7. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Co-author DOI 10.1016/j.ejca.2022.12.009↗
  8. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  9. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
  10. Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. Co-author DOI 10.3390/jcm11164905↗
  11. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… Co-author DOI 10.1007/s00066-020-01680-2↗
  12. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma -… Co-author DOI 10.1016/j.ejca.2021.03.036↗
  13. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Co-author DOI 10.3389/fonc.2021.670396↗
  14. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic can… Last author DOI 10.1016/j.ejca.2020.06.032↗
  15. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Co-author DOI 10.1158/1078-0432.ccr-19-3034↗
  16. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. Co-author DOI 10.1186/s12885-019-6148-5↗
  17. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-018-0093-y↗
  18. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Co-author DOI 10.1038/s41416-018-0246-z↗
  19. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.016↗
  20. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… Co-author DOI 10.1200/jco.2017.72.6463↗
  21. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Co-author DOI 10.1016/j.prp.2016.06.001↗
  22. Gemcitabine-resistant pancreatic cancer: a second-line option. Co-author DOI 10.1016/s0140-6736(15)01035-1↗
  23. Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. Co-author DOI 10.1002/jso.23951↗
  24. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treat… Co-author DOI 10.1016/j.ejca.2015.05.005↗
  25. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Co-author DOI 10.1159/000441310↗
  26. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. Co-author DOI 10.1200/jco.2014.55.1481↗
  27. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Co-author DOI 10.1016/j.ctrv.2014.07.003↗
  28. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Co-author DOI 10.1038/bjc.2014.495↗
  29. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Co-author DOI 10.1093/annonc/mdu084↗
  30. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. Last author DOI 10.1159/000358890↗
  31. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from … Co-author DOI 10.1200/jco.2013.53.6995↗
  32. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Co-author DOI 10.1001/jama.2013.279201↗
  33. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. Last author DOI 10.1002/jso.23409↗
  34. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  35. First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CO… Last author DOI 10.1007/s00280-011-1602-3↗
  36. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase I… Last author DOI 10.1016/j.ejca.2011.04.011↗
  37. K-ras Mutations in the Plasma Correspond to Computed Tomographic Findings in Patients With Pancreatic Cancer Last author DOI 10.1097/mpa.0b013e3182289118↗
  38. Transforming growth factor beta in pancreatic cancer. First author DOI 10.2174/138920111798808356↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Uwe Pelzer · 21 shared papers, 2011–2024 · strength 1.55
  2. Hanno B. Riess · 21 shared papers, 2011–2024 · strength 1.41
  3. Marianne Sinn · 19 shared papers, 2013–2024 · strength 1.41
  4. Jana Käthe Striefler · 15 shared papers, 2013–2022 · strength 1.09
  5. Rainer Fietkau · 5 shared papers, 2021–2026 · strength 1.00
  6. Marcus Bahra · 14 shared papers, 2013–2023 · strength 0.99
  7. Sabine Semrau · 4 shared papers, 2021–2026 · strength 0.89
  8. Stefan Hubert Boeck · 5 shared papers, 2021–2026 · strength 0.78
  9. Anke Reinacher‐Schick · 5 shared papers, 2019–2026 · strength 0.74
  10. Michael B. Ghadimi · 6 shared papers, 2017–2026 · strength 0.72
  11. Robert Grützmann · 5 shared papers, 2017–2026 · strength 0.63
  12. Dorota Łubgan · 4 shared papers, 2019–2026 · strength 0.58
  13. Waldemar H. Uhl · 4 shared papers, 2019–2026 · strength 0.58
  14. Henriette Golcher · 4 shared papers, 2019–2026 · strength 0.58
  15. Uwe A. Wittel · 4 shared papers, 2019–2026 · strength 0.58
  16. Dominik Paul Modest · 4 shared papers, 2021–2024 · strength 0.57
  17. Bruno Valentin Sinn · 9 shared papers, 2013–2021 · strength 0.54
  18. Carsten Denkert · 9 shared papers, 2013–2021 · strength 0.54
  19. Philipp Lohneis · 8 shared papers, 2014–2021 · strength 0.51
  20. Jens Stieler · 10 shared papers, 2011–2022 · strength 0.48
  21. Dirk Waldschmidt · 3 shared papers, 2017–2026 · strength 0.46
  22. Volker Heinemann · 3 shared papers, 2023–2024 · strength 0.44
  23. Andrea Tannapfel · 2 shared papers, 2025–2026 · strength 0.40
  24. Markus Hecht · 2 shared papers, 2025–2026 · strength 0.40
  25. Annika Kurreck · 3 shared papers, 2021–2024 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.